Methotrexate for the treatment of juvenile idiopathic arthritis: Process to approval for JIA indication in Japan

Modern Rheumatology

Volumn 19, Issue 1, 2009, Pages 1-11

  Mori, Masaaki ^a   Naruto, Takuya ^a   Imagawa, Tomoyuki ^a   Murata, Takuji ^b   Takei, Syuji ^c   Tomiita, Minako ^d   Itoh, Yasuhiko ^e   Fujikawa, Satoshi ^f   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Childhood; Expansion of indication; Juvenile idiopathic arthritis; Methotrexate

Indexed keywords

ACETYLSALICYLIC ACID; AURANOFIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; HEPATITIS B VACCINE; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PIROXICAM; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SULINDAC; TOLMETIN;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CHICKENPOX; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATOMYOSITIS; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSTHYMIA; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HALF LIFE TIME; HEMATURIA; HEPATOBILIARY DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE DISORDER; LEUKOPENIA; LIVER DISEASE; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG LESION; MALAISE; MAXIMUM PLASMA CONCENTRATION; MUCOSAL DISEASE; NAUSEA; NAUSEA AND VOMITING; OSTEOARTHRITIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; DRUG APPROVAL; HUMANS; JAPAN; METHOTREXATE; MORBIDITY; TREATMENT OUTCOME;

EID: 60149105640     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0123-3     Document Type: Review

References (39)

1. Harrington J. Developmental issues in adolescence and the impact of rheumatic disease. In: Isenberg DA, Miller JJ, editors. Adolescent rheumatology. London: Martin Dunitz; 2000. p. 21-34.
2. Petty RE, Cassidy JT. Chronic arthritis, poly arthritis, oligoarthritis, systemic arthritis. In: Cassidy JT, Petty RE, Laxer RM, Linsley CB, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier Saunders; 2005. p. 206-303.
3. Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children. Acta Paediatr Jpn. 1997;39:242-4.
4. Yokota S. Investigation of the actual situation and medical administrative policy for QOL improvement in patients with juvenile rheumatoid arthritis. Public Welfare Labor Science Study, 2000.
5. Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases. Br J Rheumatol. 1993;32:73-7.
6. Cassidy JT. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis. J Pediatr. 1998;133:179-80.
7. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child. 2003;88:197-200.
8. Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis. Therapy. 1999;81:766-72.
9. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
10. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849-57.
11. National Institute for Clinical Excellence March 2002. Technology Appraisal No. 35. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. http://www.nice.org.uk/.
12. Past package inserts for Rheumatrex® Capsule 2 mg. Revised February 2007.
13. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-63.
14. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic diseases. Ann Rheum Dis. 2000;59(Suppl 1):21-27.
15. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763-9.
16. Brewer EJ Jr, Giannini EH. Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design. J Rheumatol. 1982;9:109-13.
17. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655-66.
18. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191-201.
19. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202-9.
20. Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis. 1998;57:38-41.
21. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol. 1997;24:2230-2.
22. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res. 1983;43:2342-5.
23. Ravelli A, Di Fuccia G, Molinaro M, Ramenghi B, Zonta L, Regazzi MB, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol. 1993;20:1573-7.
24. Albertioni F, Flato B, Seideman P, Beck O, Vinje O, Peterson C, et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol. 1995;47:507-11.
25. Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol. 1990;17:1469-73.
26. Pinkerton CR, Welshman SG, Glasgow JF, Bridges JM. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet. 1980;2:944-6.
27. Dupuis LL, Koren G, Silverman ED, Laxer RM. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol. 1995;22:1570-3.
28. Bannwarth B, Pehourcq F, Lequen L. Pharmacokinetics of methotrexate in rheumatoid arthritis: Therapeutic implications. Therapie. 1997;52:129-32.
29. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1989;32:677-81.
30. Kasapcopur O, Cullu F, Kamburoglu-Goksel A, Cam H, Akdenizli E, Calykan S, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1128-30.
31. Takken T, Van Der Net J, Helders PJ. Methotrexate for treating juvenile idiopathic arthritis. Cochrane Database Syst Rev 2001:CD003129.
32. Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A, Kuzmina N. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1993;23:34-46.
33. Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol. 2000;27:1830-3.
34. Yokota S. Recent topics on rheumatism and collagen diseases in childhood. Nippon Naika Gakkai Zasshi 2007;96:2226-34 (in Japanese).
35. Aihara Y, et al. The MTX therapy for juvenile idiopathic arthritis. Ryumach 40:336, 2000 (Proceedings of the 44th meeting of the Japan College of Rheumatology) (in Japanese).
36. Nelson Textbook of Pediatrics (17th editon, 2004) Chapter 114 http://www.mdconsult.com/das/book/0/view/1175/instruct.html.
37. Proper use information for Rheumatrex® Capsule 2 mg (vol 12): Reexamination application material (Use Result Surveillance and Special Use-Result Surveillance), prepared in January 2007.
38. Proper use information for Enbrel® Subcutaneous injection 25 mg (vol 6): All cases surveillance interim report II (n = 7,091 cases), prepared in June 2007.
39. Kawai S, Ochi T, Kondo H, Nishioka K, Nobuyuki N, Yoshino S. A survey of the doses of methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis. Ryumachi 2002;42:76-9 (in Japanese).